Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abexinostat - Xynomic Pharmaceuticals

Drug Profile

Abexinostat - Xynomic Pharmaceuticals

Alternative Names: Abexinostat hydrochloride; CG-781; CRA-024781; CRA-024781 HCl; CRA-024781-01; PCI-24781; PCI-24781-01; S 78454; S78454-1

Latest Information Update: 18 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celera Genomics Group
  • Developer GSK; Janssen Inc; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Pharmacyclics; Servier; University of California at San Francisco; Xynomic Pharmaceuticals
  • Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Rad51 recombinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal cell carcinoma
  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma; Sarcoma
  • Phase I Glioma
  • No development reported Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 26 Jun 2023 Phase-I clinical trials in Glioma (Recurrent, Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT05698524)
  • 26 Jan 2023 Xynomic Pharmaceuticals plans a phase I trial for Glioma (Recurrent, Combination therapy, Late-stage disease, Second-line therapy or greater) (NCT05698524)
  • 03 Jun 2022 Interim efficacy and adverse events data from a phase II trial in Follicular lymphoma presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top